Pfizer (PFE) Inventory Average (2009 - 2026)
Pfizer (PFE) posted quarterly Inventory Average of $10.7 billion for Q1 2026, down 1.76% year-over-year from $10.9 billion in Q1 2025, and down 3.62% quarter-over-quarter from $11.1 billion in Q4 2025.
Pfizer (PFE) Inventory Average (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Inventory Average for 18 consecutive years, with $10.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Inventory Average fell 1.76% year-over-year to $10.7 billion; the TTM figure through Mar 2026 stood at $10.7 billion (down 1.76% YoY), while the FY2025 annual figure was $10.8 billion, down 4.73% from the prior year.
- Inventory Average declined to $10.7 billion in Q1 2026 per PFE's latest filing, from $11.1 billion in the prior quarter.
- Across five years, Inventory Average topped out at $11.6 billion in Q3 2024 and bottomed at $9.3 billion in Q2 2023.
- Historically, Inventory Average has averaged $10.7 billion across 5 years, with a median of $10.9 billion in 2025.
- Annual changes were most pronounced in 2022 — Inventory Average increased 17.15% — and 2023, when it slipped 2.85%.
- Pfizer's Inventory Average stood at $10.2 billion in 2022, then decreased by 2.85% to $9.9 billion in 2023, then rose by 13.71% to $11.3 billion in 2024, then fell by 1.99% to $11.1 billion in 2025, then declined by 3.62% to $10.7 billion in 2026.
- Business Quant data shows PFE's Inventory Average at $10.7 billion in Q1 2026, $11.1 billion in Q4 2025, and $11.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | 14.86 Bn |
| 2 | AbbVie | 470.02 Bn | 463.46 Bn | 12.70 Bn | 5.09 Bn |
| 3 | Merck | 379.06 Bn | 371.92 Bn | 12.21 Bn | 6.34 Bn |
| 4 | Novartis Ag | 302.95 Bn | 295.26 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.68 Bn | 252.78 Bn | 12.86 Bn | 6.75 Bn |
| 6 | Amgen | 236.97 Bn | 222.98 Bn | 7.24 Bn | 6.20 Bn |
| 7 | Gilead Sciences | 182.78 Bn | 179.60 Bn | 6.22 Bn | 1.93 Bn |
| 8 | Pfizer | 161.51 Bn | 149.81 Bn | 10.94 Bn | 10.31 Bn |
| 9 | Gsk | 105.54 Bn | 101.37 Bn | 8.24 Bn | 8.36 Bn |
| 10 | Sanofi | 55.04 Bn | 47.66 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 10.31 Bn |
| Mar 29, 2026 | 10.66 Bn |
| Dec 31, 2025 | 11.06 Bn |
| Sep 28, 2025 | 11.57 Bn |
| Jun 29, 2025 | 11.26 Bn |
| Mar 30, 2025 | 10.85 Bn |
| Dec 31, 2024 | 11.29 Bn |
| Sep 29, 2024 | 11.58 Bn |
| Jun 30, 2024 | 11.17 Bn |
| Mar 31, 2024 | 10.54 Bn |
| Jul 2, 2023 | 9.93 Bn |
| Apr 2, 2023 | 9.26 Bn |
| Jul 3, 2022 | 10.22 Bn |
| Apr 3, 2022 | 9.52 Bn |
| Dec 31, 2021 | 8.85 Bn |
| Oct 3, 2021 | 8.79 Bn |
| Jul 4, 2021 | 8.72 Bn |
| Apr 4, 2021 | 8.26 Bn |
| Dec 31, 2020 | 8.66 Bn |
| Sep 27, 2020 | 8.93 Bn |